Home > Boards > US OTC > Biotechs > BioVie Inc. (BIVI)

As info: Cirrhosis biotech BioVie revives $15 million

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
ejobkar Member Profile
 
Followed By 1
Posts 182
Boards Moderated 0
Alias Born 03/05/12
160x600 placeholder
ejobkar   Wednesday, 10/02/19 06:55:25 PM
Re: None
Post # of 747 
As info: Cirrhosis biotech BioVie revives $15 million Nasdaq IPO plans in latest filing

"BioVie, an early stage biotech developing therapies for cirrhosis, filed an amended S-1 on Wednesday with the SEC to raise up to $15 million, based on its registered offering of 1.7 million units at $8.75, the as-converted last close of its stock on the OTCQB (BIVI). At that price, it would command a post-offering market cap of $94 million. The company added warrants in the latest filing; the units consist of one share and one-half warrant, with full warrants exercisable at 125% of the offer price. Because the deal was re-launched as a unit offering, Renaissance Capital is no longer including BioVie in our IPO stats."

BioVie had previously planned to raise $15 million in August, when its shares traded at $11.44 ($77 million market cap), but postponed the offering."

The Los Angeles, CA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol BIVI. ThinkEquity is the sole bookrunner on the deal.


https://www.renaissancecapital.com/IPO-Center/News/65259/Cirrhosis-biotech-BioVie-revives-IPO-plans-in-latest-filing

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist